Aurora Cannabis Inc vs Danaher Corporation — how do they compare? Aurora Cannabis Inc trades at $3.4 (market cap $223.59M), while Danaher Corporation trades at $206.12 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 652.2× Aurora Cannabis Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | DHR | |
|---|---|---|
Market Cap | $223.59M | $145.83B |
Sector | Health | Health |
52-Week High | $6.23 | $242.05 |
52-Week Low | $2.58 | $161.91 |
Enterprise Value | $168.09M | $168.04B |
Dividend Yield | — | 0.77% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Trailing returns across standard periods
Latest headlines on both assets
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →